Frontiers in Immunology (Feb 2023)
Immune-related risk score: An immune-cell-pair-based prognostic model for cutaneous melanoma
- Mingjia Li,
- Mingjia Li,
- Mingjia Li,
- Mingjia Li,
- Mingjia Li,
- Mingjia Li,
- Xinrui Long,
- Xinrui Long,
- Xinrui Long,
- Xinrui Long,
- Xinrui Long,
- Wenbo Bu,
- Guanxiong Zhang,
- Guanxiong Zhang,
- Guanxiong Zhang,
- Guanxiong Zhang,
- Guanxiong Zhang,
- Guangtong Deng,
- Guangtong Deng,
- Guangtong Deng,
- Guangtong Deng,
- Guangtong Deng,
- Yuancheng Liu,
- Yuancheng Liu,
- Yuancheng Liu,
- Yuancheng Liu,
- Yuancheng Liu,
- Juan Su,
- Juan Su,
- Juan Su,
- Juan Su,
- Juan Su,
- Kai Huang,
- Kai Huang,
- Kai Huang,
- Kai Huang,
- Kai Huang
Affiliations
- Mingjia Li
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
- Mingjia Li
- National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China
- Mingjia Li
- Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha, China
- Mingjia Li
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
- Mingjia Li
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Mingjia Li
- Department of Dermatology, Peking University First Hospital, Peking University, Beijing, China
- Xinrui Long
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
- Xinrui Long
- National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China
- Xinrui Long
- Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha, China
- Xinrui Long
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
- Xinrui Long
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Wenbo Bu
- Department of Dermatological Surgery, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College, Nanjing, China
- Guanxiong Zhang
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
- Guanxiong Zhang
- National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China
- Guanxiong Zhang
- Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha, China
- Guanxiong Zhang
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
- Guanxiong Zhang
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Guangtong Deng
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
- Guangtong Deng
- National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China
- Guangtong Deng
- Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha, China
- Guangtong Deng
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
- Guangtong Deng
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Yuancheng Liu
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
- Yuancheng Liu
- National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China
- Yuancheng Liu
- Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha, China
- Yuancheng Liu
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
- Yuancheng Liu
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Juan Su
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
- Juan Su
- National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China
- Juan Su
- Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha, China
- Juan Su
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
- Juan Su
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Kai Huang
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
- Kai Huang
- National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China
- Kai Huang
- Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha, China
- Kai Huang
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
- Kai Huang
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- DOI
- https://doi.org/10.3389/fimmu.2023.1112181
- Journal volume & issue
-
Vol. 14
Abstract
BackgroundMelanoma is among the most malignant immunologic tumor types and is associated with high mortality. However, a considerable number of melanoma patients cannot benefit from immunotherapy owing to individual differences. This study attempts to build a novel prediction model of melanoma that fully considers individual differences in the tumor microenvironment.MethodsAn immune-related risk score (IRRS) was constructed based on cutaneous melanoma data from The Cancer Genome Atlas (TCGA). Single-sample gene set enrichment analysis (ssGSEA) was used to calculate immune enrichment scores of 28 immune cell signatures. We performed pairwise comparisons to obtain scores for cell pairs based on the difference in the abundance of immune cells within each sample. The resulting cell pair scores, in the form of a matrix of relative values of immune cells, formed the core of the IRRS.ResultsThe area under the curve (AUC) for the IRRS was over 0.700, and when the IRRS was combined with clinical information, the AUC reached 0.785, 0.817, and 0.801 for the 1-, 3-, and 5-year survival, respectively. Differentially expressed genes between the two groups were enriched in staphylococcal infection and estrogen metabolism pathway. The low IRRS group showed a better immunotherapeutic response and exhibited more neoantigens, richer T-cell receptor and B-cell receptor diversity, and higher tumor mutation burden.ConclusionThe IRRS enables a good prediction of prognosis and immunotherapy effect, based on the difference in the relative abundance of different types of infiltrating immune cells, and could provide support for further research in melanoma.
Keywords
